Pharmaceutical Bioassays

Name: Pharmaceutical Bioassays | Methods and Applications
Brand: Wiley
Price: 141.99 EUR
Availability: OnlineOnly

Methods and Applications

Shiqi Peng Ming Zhao(Autor*in)

Wiley (Verlag)

Erschienen am 17. Dezember 2009

464 Seiten

E-Book

PDF mit Adobe-DRM

Systemvoraussetzungen

978-0-470-52219-6 (ISBN)

141,99 €inkl. 7% MwSt.

Systemvoraussetzungen

für PDF mit Adobe-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

Weitere Details

Weitere Ausgaben

Personen

Inhalt

1 - PHARMACEUTICAL BIOASSAYS [Seite 3]
1.1 - CONTENTS [Seite 7]
1.2 - Preface [Seite 23]
1.3 - Contributors [Seite 25]
1.4 - 1 Methods and Applications of Anticancer Bioassays [Seite 27]
1.4.1 - 1.1 MTT Assay for Six Carcinoma Cells [Seite 28]
1.4.2 - 1.2 Flow Cytometric Assay for Cell Apoptosis [Seite 29]
1.4.3 - 1.3 DNA Fragmentation Assay [Seite 29]
1.4.4 - 1.4 Bcl-XL/BH3 Interaction Assay [Seite 29]
1.4.5 - 1.5 Dissociation-Enhanced Lanthanide Fluoro-Immunoassay (DELFIA) [Seite 30]
1.4.6 - 1.6 Ishikawa Cell and Rat Assay for Detecting Antiestrogens [Seite 31]
1.4.7 - 1.7 ATP Assay for Eight Cells [Seite 33]
1.4.8 - 1.8 AP Activity Assay [Seite 33]
1.4.9 - 1.9 Tumor Endothelial Cell Tube Formation Assay [Seite 34]
1.4.10 - 1.10 Antiangiogenic Assay [Seite 35]
1.4.11 - 1.11 In Vivo Hollow Fiber Assay [Seite 36]
1.4.12 - 1.12 VX2 Rabbit Lung Assay [Seite 37]
1.4.13 - 1.13 Insulin-Like Growth Factor-I-Induced Kinase Receptor Activation Assay [Seite 37]
1.4.14 - 1.14 Insulin-Like gD.trkA-Induced Kinase Receptor Activation Assay [Seite 38]
1.4.15 - 1.15 UV Spectra-Based Calf Thymus DNA Intercalation Assay [Seite 38]
1.4.16 - 1.16 Fluorescence Spectra-Based Calf Thymus DNA Intercalation Assay [Seite 39]
1.4.17 - 1.17 P-Glycoprotein Pump in MCF-7R Cells Assay [Seite 39]
1.4.18 - 1.18 P-Glycoprotein Pump-Related Efflux Carriers Assay [Seite 40]
1.4.19 - 1.19 [(3)H]Substrate Transport Inhibition Assay [Seite 41]
1.4.20 - 1.20 Lactate Dehydrogenase Release Assay [Seite 41]
1.4.21 - 1.21 Functional Assay of Mitochondrial P-gp [Seite 42]
1.4.22 - 1.22 Resistance Index Value Assay [Seite 42]
1.4.23 - References and Notes [Seite 43]
1.5 - 2 Methods and Applications of Antiviral Assays [Seite 49]
1.5.1 - 2.1 Nonradioactive HIV-1 RT Activity Assay [Seite 50]
1.5.2 - 2.2 Respiratory Syncytial Virus Assay [Seite 50]
1.5.3 - 2.3 Influenza Virus Types A and B Assay [Seite 50]
1.5.4 - 2.4 Nasal Exhaled NO Concentration Assay [Seite 51]
1.5.5 - 2.5 Nasal NOS2 mRNA Quantity Assay [Seite 51]
1.5.6 - 2.6 RT-PCR and Swine Assay for Anti-HEV Antibody [Seite 52]
1.5.7 - 2.7 HIV-1 Protease and Reverse Transcriptase Kinetic Assay [Seite 52]
1.5.8 - 2.8 Anti-HIV Assay [Seite 53]
1.5.9 - 2.9 Robust Antiviral Assays [Seite 54]
1.5.10 - 2.10 HIV/SIV Fusion Assay [Seite 54]
1.5.11 - 2.11 Rapid DNA Hybridization Assay [Seite 55]
1.5.12 - 2.12 Antiviral Screening Assay for HepAD38 Cell Cultures [Seite 55]
1.5.13 - 2.13 Trak-C HCV Core Assay [Seite 57]
1.5.14 - References and Notes [Seite 59]
1.6 - 3 Methods and Applications of Antitubercular Assays [Seite 65]
1.6.1 - 3.1 Mycobacterium tuberculosis Assay [Seite 65]
1.6.2 - 3.2 DNA Polymerase ? Lyase Assay [Seite 66]
1.6.3 - 3.3 Agar Dilution Assay for In Vitro Antitubercular Activity [Seite 67]
1.6.4 - 3.4 Microplate Alamar Blue Assay for In Vitro Antitubercular Activity [Seite 67]
1.6.5 - 3.5 Radiometric Respiratory Assay for In Vitro Antitubercular Activity [Seite 68]
1.6.6 - 3.6 Mycobacterium bovis BCG Inhibition Assay [Seite 68]
1.6.7 - References and Notes [Seite 69]
1.7 - 4 Methods and Applications of Thrombus-Related Assays [Seite 71]
1.7.1 - 4.1 In Vitro Anti-Platelet Aggregation Assay [Seite 72]
1.7.2 - 4.2 Fibrinolytic Area Assay [Seite 73]
1.7.3 - 4.3 TXB(2) and PGD(2) TLC Assay [Seite 73]
1.7.4 - 4.4 TXA(2) Synthase Activity Assay [Seite 74]
1.7.5 - 4.5 [Ca(2+)](i) Measuring Assay [Seite 74]
1.7.6 - 4.6 Arachidonic Acid Liberation Assay [Seite 74]
1.7.7 - 4.7 Serotonin Secretion Assay [Seite 74]
1.7.8 - 4.8 cAMP Release Assay [Seite 75]
1.7.9 - 4.9 Ex Vivo Anti-Platelet Aggregation Assay for Patients [Seite 75]
1.7.10 - 4.10 ATP Release Assay [Seite 76]
1.7.11 - 4.11 PAF-Induced Mice Mortality Assay [Seite 76]
1.7.12 - 4.12 PGE(2) and TXB(2) ELISA [Seite 76]
1.7.13 - 4.13 Thrombelastograph Assay [Seite 77]
1.7.14 - 4.14 Image-Monitored FeCl(3)-Induced Thrombosis Assay for Rat [Seite 77]
1.7.15 - 4.15 Weight-Monitored FeCl(3)-Induced Thrombosis Assay for Rats [Seite 78]
1.7.16 - 4.16 Occlusion Time-Monitored FeCl(3)-Induced Thrombosis Assay for Pig [Seite 78]
1.7.17 - 4.17 Doppler Blood Flow-Monitored FeCl(3)-Induced Thrombosis Assay for Mouse [Seite 79]
1.7.18 - 4.18 Rat Groin Flap Assay [Seite 80]
1.7.19 - 4.19 Ferret Acute Thrombosis Assay [Seite 81]
1.7.20 - 4.20 Rat Acute Thrombosis Assay [Seite 82]
1.7.21 - 4.21 Arteriovenous Shunt Assay [Seite 82]
1.7.22 - 4.22 Plasma Clotting Time Assay [Seite 82]
1.7.23 - 4.23 Thromboembolic Photochemical Assay for Repeated Stroke in Mice [Seite 83]
1.7.24 - 4.24 Euglobulin Clot Lysis Assay [Seite 84]
1.7.25 - 4.25 Clot Formation and Lysis (CloFAL) Assay [Seite 85]
1.7.26 - 4.26 Fibrin Microplate Assay [Seite 85]
1.7.27 - 4.27 Fibrinolytic Activity Assay [Seite 86]
1.7.28 - 4.28 Fibrinolysis Assay [Seite 86]
1.7.29 - 4.29 Thrombolytic Assay [Seite 87]
1.7.30 - References and Notes [Seite 88]
1.8 - 5 Methods and Applications of Anticoagulation Assays [Seite 91]
1.8.1 - 5.1 Ecarin Chromogenic Assay [Seite 92]
1.8.2 - 5.2 Anticoagulation Activity Assay in an In Vitro System [Seite 93]
1.8.3 - 5.3 Anticoagulation Activity Assays in an In Vivo System [Seite 93]
1.8.4 - 5.4 Rat Thrombosis Assay [Seite 94]
1.8.5 - 5.5 In Vivo Microvascular IVC Blood Flow Assay [Seite 94]
1.8.6 - 5.6 Owren PT Assay [Seite 94]
1.8.7 - 5.7 Rabbit Double-Balloon Injury Assay [Seite 95]
1.8.8 - 5.8 A Rapid Point-of-Care Assay for Enoxaparin [Seite 96]
1.8.9 - 5.9 Thromboplastin Clotting Assay [Seite 97]
1.8.10 - 5.10 Rat Assay for Reproducible Stasis-Induced Venous Thrombosis [Seite 97]
1.8.11 - 5.11 In Vivo ACT II/Ecarin Clotting Time Assay [Seite 98]
1.8.12 - 5.12 Ex Vivo and In Vivo Anticoagulation Assay [Seite 99]
1.8.13 - 5.13 Plasma-Based Ecarin Clotting Time Assay for r-Hirudin [Seite 100]
1.8.14 - 5.14 Protamine Titration for Heparin in Whole Blood [Seite 101]
1.8.15 - 5.15 Automated Assay Evaluating Response of Kaolin ACT to Heparin [Seite 102]
1.8.16 - 5.16 Platelet/Monocyte Interaction-Based PM Exposure Mouse Assay [Seite 103]
1.8.17 - 5.17 Mouse Tail-Bleeding Time Assay [Seite 104]
1.8.18 - 5.18 MRI Assay for Rabbit Atherosclerotic Lesions [Seite 104]
1.8.19 - 5.19 Spiral Computed Tomography Assay [Seite 105]
1.8.20 - 5.20 Duplex Ultrasound Assay [Seite 106]
1.8.21 - 5.21 Standard Hemochron Assay [Seite 107]
1.8.22 - 5.22 Platelet Serotonin Release Assay [Seite 107]
1.8.23 - 5.23 Activated Partial Thromboplastin Time Assay [Seite 108]
1.8.24 - 5.24 Rat Stroke Outcome Assay [Seite 108]
1.8.25 - References and Notes [Seite 109]
1.9 - 6 Methods and Applications of Blood Pressure-Related Assays [Seite 113]
1.9.1 - 6.1 Human Plasma New Pressor Protein Assay [Seite 114]
1.9.2 - 6.2 Pulmonary Hypertension Assay [Seite 115]
1.9.3 - 6.3 Coronary Arteries Constriction Assay [Seite 116]
1.9.4 - 6.4 MRI and Brain Natriuretic Peptide Assays [Seite 116]
1.9.5 - 6.5 Competition Enzyme-Linked Immunosorbent Assay [Seite 117]
1.9.6 - 6.6 Right Ventricular Pressure Assay [Seite 118]
1.9.7 - 6.7 Plasma Nitrite/Nitrate Concentration Assay [Seite 118]
1.9.8 - 6.8 Adeno-Associated Virus Vector-Caused Rat Pulmonary Artery Pressure Assay [Seite 118]
1.9.9 - 6.9 Adeno-Associated Virus Vector-Caused Rat Protein and mRNA Assay [Seite 119]
1.9.10 - 6.10 N-Terminal pro-Brain Natriuretic Peptide (N-T proBNP) Assay [Seite 119]
1.9.11 - 6.11 Middle Cerebral Artery Occlusion Assay [Seite 120]
1.9.12 - 6.12 Vascular Endothelial Growth Factor Level Assay [Seite 121]
1.9.13 - 6.13 Antispasmodic Agent In Vivo Action Assay [Seite 121]
1.9.14 - 6.14 Temperature Assay in Awake Subjects [Seite 122]
1.9.15 - References and Notes [Seite 123]
1.10 - 7 Methods and Applications of Assays Related to Parkinson's Disease and Graves' Disease [Seite 127]
1.10.1 - 7.1 Flow Cytometric Assay for Cellular DNA Content and Caspase-3 [Seite 128]
1.10.2 - 7.2 Swine Resuscitation Assay [Seite 129]
1.10.3 - 7.3 HTLV-tax1 or pMuLV-SV-nlslacZ Vectors Transfected Cell Assay [Seite 130]
1.10.4 - 7.4 Parkinsonian Rat Assay [Seite 130]
1.10.5 - 7.5 ELISA for Nerve Growth Factor Antigen [Seite 131]
1.10.6 - 7.6 Assay for ?-Nerve Growth Factor Levels in Cerebrospinal Fluid [Seite 132]
1.10.7 - 7.7 MDCK Scatter Assay [Seite 133]
1.10.8 - 7.8 Facial Nerve and Spinal Root Avulsions [Seite 134]
1.10.9 - 7.9 TRAb Assays [Seite 134]
1.10.10 - 7.10 Human Thyrotropin Receptor (hTSHR) Assay [Seite 135]
1.10.11 - 7.11 Soluble ICAM-1, TSAb, and TBIAb Activity Assays [Seite 137]
1.10.12 - 7.12 Microarray Immunoassay for hTSHr Production [Seite 138]
1.10.13 - 7.13 Affinity Assay for [(35)S]GTP?S Binding to Gas/olf [Seite 139]
1.10.14 - 7.14 Tissue Segment Binding Assay for ?(1B)-Adrenoceptor [Seite 140]
1.10.15 - 7.15 Membrane Binding Assay with Rat Cerebral Cortex for ?(1B)-Adrenoceptor [Seite 141]
1.10.16 - 7.16 Whole Cell Binding Assay for ?(1B)-Adrenoceptor [Seite 141]
1.10.17 - 7.17 Functional Assay for ?(1A,B)-Adrenoceptor [Seite 142]
1.10.18 - 7.18 Rat Neuroprotective Assay [Seite 142]
1.10.19 - 7.19 GABA-Benzodiazepine Receptor Assay [Seite 143]
1.10.20 - 7.20 Forced Swimming and Tail Suspension Assays [Seite 143]
1.10.21 - 7.21 IGF-I Kinase Receptor Activation (KIRA) Assay [Seite 144]
1.10.22 - 7.22 gD.trkA Kinase Receptor Activation (KIRA) Assay [Seite 144]
1.10.23 - 7.23 gD.trk KIRA-ELISA [Seite 144]
1.10.24 - 7.24 Assays for Cannabinoid Receptors in Rat Cerebella or Mouse Brains [Seite 146]
1.10.25 - References and Notes [Seite 147]
1.11 - 8 Methods and Applications of Alzheimer's Disease Assays [Seite 151]
1.11.1 - 8.1 Assay for Oxidative Stress in Cerebral Cortex of AD Mice [Seite 152]
1.11.2 - 8.2 Reporter Assay for Primary Neuronal Cultures [Seite 153]
1.11.3 - 8.3 Electrophoretic Mobility Shift Assay (EMSA) [Seite 153]
1.11.4 - 8.4 Binding Assays Using Aggregated A? Peptide in Solution [Seite 153]
1.11.5 - 8.5 Assay for Muscarinic Receptor 1 in Alzheimer's Dementia Model [Seite 154]
1.11.6 - 8.6 ?-Secretase Activity Assay [Seite 154]
1.11.7 - 8.7 A? Fibril Binding Assay [Seite 155]
1.11.8 - 8.8 TLC and Microplate Assays for Acetylcholinesterase Inhibitors [Seite 155]
1.11.9 - 8.9 Immunocapture Assay Measuring Specific Enzyme Activity of Neprilysin [Seite 156]
1.11.10 - 8.10 In Vivo AChE Inhibition Assay [Seite 157]
1.11.11 - 8.11 Single Particle Assay for A? Aggregates [Seite 158]
1.11.12 - 8.12 Indirect Immunofluorescence Assay [Seite 159]
1.11.13 - 8.13 Mouse Behavioral Assays [Seite 159]
1.11.14 - 8.14 Center of Pressure (CoP) Assay in Mice [Seite 161]
1.11.15 - 8.15 Assay for Plasma Levels of DJ-1 [Seite 162]
1.11.16 - 8.16 Membrane Filter Assay for Tau Aggregation [Seite 163]
1.11.17 - 8.17 Assays for Motor Neuron Degeneration [Seite 164]
1.11.18 - 8.18 HPLC Assay for Neuroprotective Agent in Mice Plasma [Seite 166]
1.11.19 - 8.19 Tissue Culture Assays for SOD1 Mutations [Seite 167]
1.11.20 - 8.20 Luciferase-Based Reporter Assay [Seite 168]
1.11.21 - References and Notes [Seite 168]
1.12 - 9 Methods and Applications of Antiosteoporosis Assays [Seite 171]
1.12.1 - 9.1 Rat Bone Mineral Density Assay [Seite 172]
1.12.2 - 9.2 Osteoblastic Cell Proliferation and Alkaline Phosphatase (ALP) Activity Assays [Seite 172]
1.12.3 - 9.3 Murine Osteoblastic MC3T3-E1 Cell Calcification and Van Kossa Assays [Seite 173]
1.12.4 - 9.4 Osteoclast Generation Assay for Male Senile Rat [Seite 174]
1.12.5 - 9.5 Bone Resorption and Recovery Related Assays [Seite 174]
1.12.6 - 9.6 Mouse Bone Mineral Density Assay [Seite 175]
1.12.7 - 9.7 PPAR-? Competitor Assay [Seite 176]
1.12.8 - 9.8 Human Serum Estrogen Level Assay [Seite 176]
1.12.9 - 9.9 Luciferase Activity Assay [Seite 176]
1.12.10 - 9.10 IL-1? and TNF-? Level Assay [Seite 176]
1.12.11 - 9.11 ER Binding and Receptor Activity Assays [Seite 177]
1.12.12 - 9.12 Fluorescent Estrogen Receptor Assay [Seite 178]
1.12.13 - 9.13 ELISA for Urinary Helical Peptide [Seite 179]
1.12.14 - 9.14 Urine Midmolecule Osteocalcin Assay [Seite 179]
1.12.15 - 9.15 BMD and Osteocalcin Assay [Seite 180]
1.12.16 - 9.16 In Vivo Antiosteoporosis Assay on Mice [Seite 180]
1.12.17 - References and Notes [Seite 181]
1.13 - 10 Methods and Applications of Immunomodulating Assays [Seite 183]
1.13.1 - 10.1 Rat Mast Cell Histamine-Release Assay [Seite 184]
1.13.2 - 10.2 Rabbit Aortic Force Assay [Seite 185]
1.13.3 - 10.3 Dopaminergic Cell Death-Based Neural Transplantation Assay [Seite 185]
1.13.4 - 10.4 Mast Cell Degranulation Assay [Seite 186]
1.13.5 - 10.5 Basophils Assay as Allergen [Seite 187]
1.13.6 - 10.6 RBL-2H3 Cell Desensitization Assay [Seite 188]
1.13.7 - 10.7 Migration Assay of Dendritic Cell from PBMCs [Seite 188]
1.13.8 - 10.8 Mouse EAE Induction Assay [Seite 189]
1.13.9 - 10.9 COSTIM Assay for DC/T-Cells [Seite 189]
1.13.10 - 10.10 Cytokine Assay for IL-6, IL-10, IL-12, and TNF-? of DCs [Seite 190]
1.13.11 - 10.11 ELISPOT Assay for DC IFN-? [Seite 191]
1.13.12 - 10.12 DC Function Assay for Evaluating Toll-like Receptor Function [Seite 192]
1.13.13 - 10.13 Migration Assay of Dendritic Cell from Bone Marrow of A/J Mice [Seite 193]
1.13.14 - 10.14 Lymphoid Organ Assay [Seite 194]
1.13.15 - 10.15 ELISA of IFN-? from Human Myelomonocytic KG-1 Cells [Seite 196]
1.13.16 - 10.16 Human Whole Blood IFN-? Assays [Seite 197]
1.13.17 - 10.17 Sheep Whole Blood IFN-? Assays [Seite 197]
1.13.18 - 10.18 ELISPOT Assay for IFN-? [Seite 198]
1.13.19 - 10.19 IFN-? RG Assay [Seite 199]
1.13.20 - 10.20 Anti-rHuEPO NAb Assay [Seite 199]
1.13.21 - 10.21 Chloramphenicol Acetyltransferase Assay [Seite 200]
1.13.22 - 10.22 Chemotaxis Assay [Seite 201]
1.13.23 - 10.23 Fibroblast-Populated Microsphere Assay [Seite 201]
1.13.24 - 10.24 Fibroblast-Populated Concentric Microsphere Assay [Seite 202]
1.13.25 - 10.25 Radial Assay of Chemotaxis [Seite 204]
1.13.26 - 10.26 Antibody Forming Cell Assay [Seite 205]
1.13.27 - 10.27 Immunosuppressive Assay [Seite 205]
1.13.28 - 10.28 Cell-Based ELISA [Seite 206]
1.13.29 - 10.29 Large Animal Lung Transplantation Assay [Seite 207]
1.13.30 - References and Notes [Seite 208]
1.14 - 11 Methods and Applications of Anti-Inflammatory Assays [Seite 213]
1.14.1 - 11.1 Adhesion Formation Assay [Seite 214]
1.14.2 - 11.2 Ligand Complex-Based Adhesion Assay [Seite 215]
1.14.3 - 11.3 Human Umbilical Vein Endothelial Cell Assay [Seite 216]
1.14.4 - 11.4 Pleurisy Mouse Assay [Seite 217]
1.14.5 - 11.5 Proliferation of PBMC Assay [Seite 218]
1.14.6 - 11.6 COX-1, COX-2, and 5-LOX Assay with [1-(14)C]Arachidonic Acid [Seite 219]
1.14.7 - 11.7 COX-1 and COX-2 Assay with Human Whole Blood [Seite 219]
1.14.8 - 11.8 o-Hydroxyleukotriene B4 Assay [Seite 220]
1.14.9 - 11.9 Leukocyte Rolling and Adherence Assay [Seite 220]
1.14.10 - 11.10 CCR5 Receptor Binding Assay [Seite 221]
1.14.11 - 11.11 Tissue Binding Affinity Assay [Seite 221]
1.14.12 - 11.12 G93A-SOD1 Transgenic Mouse Assay [Seite 222]
1.14.13 - 11.13 MCP-1-Induced ERK1 and ERK2 Phosphorylation Assay [Seite 223]
1.14.14 - 11.14 LPS- and IL-6-Induced ERK1 and ERK2 Phosphorylation Assay [Seite 224]
1.14.15 - 11.15 ELA4.NOB-1/CTLL Cell Assay [Seite 225]
1.14.16 - 11.16 FK506 Binding Protein 51 (FKBP51) mRNA Assay [Seite 226]
1.14.17 - 11.17 Xylene-Induced Ear Edema Assay [Seite 227]
1.14.18 - References and Notes [Seite 227]
1.15 - 12 Methods and Applications of Antioxidant Activity Assays [Seite 231]
1.15.1 - 12.1 Blood and Plasma Total Antioxidant Capacity (TAC) Assay [Seite 232]
1.15.2 - 12.2 Ferric Reducing-Antioxidant Power (FRAP) Assay [Seite 233]
1.15.3 - 12.3 Human LDL Oxidation Assay [Seite 233]
1.15.4 - 12.4 DPPH Radical Cation Scavenging Assay [Seite 233]
1.15.5 - 12.5 ABTS(+) Radical Cation Scavenging Assay [Seite 234]
1.15.6 - 12.6 Lipid Peroxidation Assay Using Rat Brain Tissue [Seite 234]
1.15.7 - 12.7 Flow-Through Chemiluminescence (FTCL) Assay [Seite 235]
1.15.8 - 12.8 Superoxide Radical Scavenging Assay [Seite 235]
1.15.9 - 12.9 Deoxyribose Assay for Hydroxyl Radical Scavenging Activity [Seite 235]
1.15.10 - 12.10 DNA Nicking Assay for Hydroxyl Radical Scavenging Activity [Seite 236]
1.15.11 - 12.11 Oxidative Lag-Time Assay [Seite 236]
1.15.12 - 12.12 TBARS and Electrophoresis Assay [Seite 236]
1.15.13 - 12.13 Reporter and Electrophoretic Mobility Shift Assay (EMSA) [Seite 237]
1.15.14 - 12.14 [Ca2(+)](cyt) Assay [Seite 237]
1.15.15 - 12.15 Quantitative Real-Time PCR Assay [Seite 238]
1.15.16 - 12.16 FT-IR-Based Assay for Antioxidation Activity of Ionol and Piperidone [Seite 238]
1.15.17 - 12.17 HPLC Assay for Antioxidation Potential of Polyphenol [Seite 239]
1.15.18 - 12.18 ROS Production Assay [Seite 239]
1.15.19 - 12.19 Rabbit LDL Oxidation Assay [Seite 239]
1.15.20 - 12.20 ROS Scavenging Assays [Seite 240]
1.15.21 - 12.21 DNA Damage Assay [Seite 241]
1.15.22 - 12.22 Egg Yolk TBARS Assay [Seite 242]
1.15.23 - 12.23 Mouse Catalase (CAT) Assay [Seite 242]
1.15.24 - 12.24 Rat Tissue TBARS Assay [Seite 242]
1.15.25 - 12.25 Antioxidant Activity Assay for ?-Carotene/Linoleic Acid System [Seite 243]
1.15.26 - 12.26 Rat Brain Tissue NO Assay [Seite 243]
1.15.27 - 12.27 Rat Brain Antioxidative Enzyme Assay [Seite 244]
1.15.28 - 12.28 Rat Brain Hippocampi Protein Oxidation Assay [Seite 244]
1.15.29 - References and Notes [Seite 245]
1.16 - 13 Methods and Applications of Analgesic Assays [Seite 249]
1.16.1 - 13.1 Algogenic Activity Assay for Rat Ureteral Stone [Seite 250]
1.16.2 - 13.2 Cold Pressor-Based Assay for Acute Pain of Healthy Volunteers [Seite 250]
1.16.3 - 13.3 Heat-Based Assay for Acute Pain of Healthy Volunteers [Seite 251]
1.16.4 - 13.4 Electrical Stimulation-Based Assay for Acute Pain of Healthy Volunteers [Seite 251]
1.16.5 - 13.5 Radiant Heat Tail-Flick Assay for Mice [Seite 252]
1.16.6 - 13.6 Pain Behaviors/Responses Assays in Rats [Seite 252]
1.16.7 - 13.7 Hot Plate Assay in Rats [Seite 253]
1.16.8 - 13.8 Plantar Assay in Rats [Seite 253]
1.16.9 - 13.9 Hot Plate Assay in Mice [Seite 253]
1.16.10 - 13.10 Paw and Tail Formalin Assays in Mice [Seite 254]
1.16.11 - 13.11 Rat Assays for Bone Cancer Pain [Seite 255]
1.16.12 - 13.12 Mouse Assay for Hindpaw Cancer Pain [Seite 255]
1.16.13 - 13.13 Visceral Pain Assay [Seite 256]
1.16.14 - 13.14 Canine Nociceptive Thermal Escape Assay in Dog [Seite 256]
1.16.15 - 13.15 Carrageenan Assay in Rats [Seite 258]
1.16.16 - 13.16 Electrophysiologic Assay for Mice with Tumor-Evoked Hyperalgesia [Seite 258]
1.16.17 - 13.17 Mouse Assay for Bone Cancer Pain [Seite 259]
1.16.18 - References and Notes [Seite 260]
1.17 - 14 Methods and Applications of Epilepsy Assays [Seite 263]
1.17.1 - 14.1 HISS Assay [Seite 264]
1.17.2 - 14.2 Mouse Locomotor Activity Assay [Seite 265]
1.17.3 - 14.3 Mouse Diathesis-Stress Assay [Seite 266]
1.17.4 - 14.4 Social Interaction Assay [Seite 266]
1.17.5 - 14.5 Spatial Learning Ability Assay for Recurrent Seizure Rats [Seite 267]
1.17.6 - 14.6 Timed PTZ Infusion Assay for Mice [Seite 267]
1.17.7 - 14.7 Timed PTZ Seizure Assay for Mice [Seite 268]
1.17.8 - 14.8 Maximal Electroconvulsions Threshold Assay for Mice [Seite 269]
1.17.9 - 14.9 MES Assay [Seite 269]
1.17.10 - 14.10 6-Hz Psychomotor Seizure Assay for Mice [Seite 270]
1.17.11 - 14.11 Subcutaneous Bicuculline and Picrotoxin Assay for Mice [Seite 270]
1.17.12 - 14.12 NMDA-Induced Convulsions Assay for Mice [Seite 270]
1.17.13 - 14.13 AGS Assay [Seite 271]
1.17.14 - 14.14 Kindled Rat Assay for Focal Seizures [Seite 271]
1.17.15 - 14.15 Cobalt/Homocysteine Assay for Status Epilepticus of Rats [Seite 272]
1.17.16 - 14.16 PTZ-Induced Kindling Assay [Seite 273]
1.17.17 - 14.17 ICES Assay for Mice [Seite 273]
1.17.18 - References and Notes [Seite 274]
1.18 - 15 Methods and Applications of Diabetes Assays [Seite 277]
1.18.1 - 15.1 Islet Xenograft Assay for Diabetic Mice [Seite 278]
1.18.2 - 15.2 Assays for Spontaneous Diabetes and Adoptive Transfer of Diabetes [Seite 278]
1.18.3 - 15.3 Oral Glucose Tolerance Assays for Patients [Seite 279]
1.18.4 - 15.4 Injection Glucose Tolerance Assays for Rats [Seite 279]
1.18.5 - 15.5 Renal Cortical TGF-?1 Protein Assays for Rats [Seite 280]
1.18.6 - 15.6 Low-Dose Streptozotocin-Treated Heminephrectomized Rat Assay [Seite 280]
1.18.7 - 15.7 Rat Early Diabetic Nephropathy Assay [Seite 281]
1.18.8 - 15.8 Urinary Endothelin-1 Excretion Assay for Type 2 Diabetes Rats [Seite 281]
1.18.9 - 15.9 Subtotally Nephrectomized Rat Assay [Seite 282]
1.18.10 - 15.10 Type 2 Diabetes Mice Assay [Seite 282]
1.18.11 - References [Seite 283]
1.19 - 16 Methods and Applications of Assays for Toxins from Microorganisms [Seite 285]
1.19.1 - 16.1 Colorimetric Yeast Assay for Trichothecene Mycotoxins [Seite 286]
1.19.2 - 16.2 Colorimetric Cell Proliferation Assay [Seite 287]
1.19.3 - 16.3 Yeast DEL Assay [Seite 288]
1.19.4 - 16.4 NCCLS and EUCAST Assays [Seite 289]
1.19.5 - 16.5 Alcohol Dehydrogenase-Based Colorimetric Assays [Seite 290]
1.19.6 - 16.6 Colorimetric Assay for Iron in Yeast [Seite 291]
1.19.7 - 16.7 Microplate Redox Assays of E. coli [Seite 291]
1.19.8 - 16.8 Ciliate Tetrahymena thermophila Assay for Trichothecene Mycotoxins [Seite 292]
1.19.9 - 16.9 Fluorescent Dyes-Based Cell Viability Assay for Triton X-100 Toxicity [Seite 293]
1.19.10 - 16.10 MTT Assay for Fusarium Mycotoxins [Seite 294]
1.19.11 - 16.11 Mortality and Frass Production Assay for Toxicity of Bacterial Strains [Seite 295]
1.19.12 - 16.12 Cell Toxicity Assay [Seite 296]
1.19.13 - 16.13 Dhase Inhibition Assay [Seite 297]
1.19.14 - 16.14 Sediment Toxicity Assay [Seite 297]
1.19.15 - 16.15 Toxicity Assay of Particle-Associated Arsenite and Mercury [Seite 298]
1.19.16 - 16.16 Genetic Toxicity Assay [Seite 299]
1.19.17 - 16.17 Microtox Assays [Seite 301]
1.19.18 - 16.18 DNA Piezoelectric Biosensor Assay [Seite 301]
1.19.19 - 16.19 Protein Phosphatase Inhibition Assay and ELISA of Microcystins [Seite 302]
1.19.20 - 16.20 Lepidium sativum Assay for Microcystin Toxicity [Seite 303]
1.19.21 - 16.21 Antiproliferative Assay for Interleukin-4 [Seite 304]
1.19.22 - References and Notes [Seite 304]
1.20 - 17 Methods and Applications of Toxicity Assays for Chemicals [Seite 307]
1.20.1 - 17.1 Lux-Fluoro Assay for Combined Genotoxicity and Cytotoxicity of Chemicals [Seite 308]
1.20.2 - 17.2 Flow Cytometry and Microscopy Based Assay [Seite 309]
1.20.3 - 17.3 Cell Transformation Assay [Seite 310]
1.20.4 - 17.4 ALIC-Based Assay for Toxicity of Chemicals in SPM [Seite 310]
1.20.5 - 17.5 Immunization in the Murine Assay [Seite 312]
1.20.6 - 17.6 Immunotoxicological Functional Assay [Seite 312]
1.20.7 - 17.7 PWM-Induced IgM Assay for Toxicity of Chemicals [Seite 314]
1.20.8 - 17.8 Tetrachlorodibenzo-p-dioxin (TCDD)-Induced Toxicity Assay [Seite 315]
1.20.9 - 17.9 H4IIE EROD Assay [Seite 317]
1.20.10 - 17.10 Rat Mutation Assay [Seite 317]
1.20.11 - 17.11 AhR and Related Assay [Seite 318]
1.20.12 - 17.12 Ectonucleotidase Expression Assay [Seite 319]
1.20.13 - 17.13 Toxicity Equivalent Quantity (TEQ) Assay [Seite 322]
1.20.14 - 17.14 Enzyme Lacking AA Epoxygenase Activity Assay [Seite 323]
1.20.15 - 17.15 Japanese Medaka Embryo-Larval Assay [Seite 327]
1.20.16 - 17.16 Green Fluorescent Protein-Based Cell Assay [Seite 328]
1.20.17 - 17.17 RACB Assay for Ovarian Toxicity of Xenobiotics [Seite 329]
1.20.18 - 17.18 Uroepithelial Cell Assay [Seite 330]
1.20.19 - 17.19 Male Rat Systemic Toxicity Assay [Seite 332]
1.20.20 - 17.20 28-Day Oral Toxicity Assay [Seite 334]
1.20.21 - 17.21 Endocrine Disruptors Assay [Seite 336]
1.20.22 - 17.22 Mating Efficiency Assay [Seite 336]
1.20.23 - 17.23 Soils Assay for Contaminants and Toxicity [Seite 337]
1.20.24 - 17.24 Rice Nitrate Reductase Activity Assay [Seite 339]
1.20.25 - 17.25 Tradescantia-Micronucleus Assay [Seite 340]
1.20.26 - 17.26 Nitric Oxide Neurotoxicity Assay [Seite 340]
1.20.27 - 17.27 EBV-Transformed Human Burkitt's Lymphoma Cell Assay [Seite 341]
1.20.28 - 17.28 Murine Bone Marrow Assay for Hemopoietic and Osteogenic Toxicity [Seite 342]
1.20.29 - 17.29 PNAR-GFP Assay for Carcinogenic Toxicity of Nitrate [Seite 343]
1.20.30 - 17.30 Brine Shrimp (Artemia salina) Assay [Seite 344]
1.20.31 - 17.31 DPPH Radical Scavenging Property Assay [Seite 344]
1.20.32 - References and Notes [Seite 345]
1.21 - 18 Methods and Applications of Hepatoxicity and Hepatoprotective Assays [Seite 351]
1.21.1 - 18.1 GST-P Enzyme-Altered Foci Assay [Seite 352]
1.21.2 - 18.2 GST-P(+) and TGF-?(+) Foci Assay [Seite 353]
1.21.3 - 18.3 Partial Hepatectomy Assay [Seite 353]
1.21.4 - 18.4 In Vivo Short-Term Liver Initiation Assay in Rats [Seite 354]
1.21.5 - 18.5 TUNEL Related Assay [Seite 354]
1.21.6 - 18.6 Hematopoietic Progenitor Cells Mobilization Assay [Seite 356]
1.21.7 - 18.7 Electrophoretic Mobility Shift Assay [Seite 357]
1.21.8 - 18.8 Telomerase Activity Assay [Seite 358]
1.21.9 - 18.9 Von Willebrand Factor (vWF) Level Assay [Seite 359]
1.21.10 - 18.10 Bromodeoxyuridine Incorporation Assay [Seite 359]
1.21.11 - 18.11 NF-?B Activation Assay [Seite 360]
1.21.12 - 18.12 Rat Summation of Initiation Activity Assay [Seite 361]
1.21.13 - 18.13 Hepatoprotective Assay [Seite 361]
1.21.14 - 18.14 Cytokine Gene Expression Assay [Seite 362]
1.21.15 - 18.15 Competitive Inhibition Assay for Immunodominance of O-Specific Polysaccharides of Gram-Negative Bacilli [Seite 363]
1.21.16 - 18.16 Marine HP Toxin Okadaic Acid (OA) Assay and ELISA [Seite 364]
1.21.17 - 18.17 Anti-GST-CTX MVIIA Antibody in Omega-Conotoxin MVIIA Assay [Seite 364]
1.21.18 - 18.18 Assays for Rituximab in Patient Plasmas [Seite 366]
1.21.19 - 18.19 Assays of TNF-?, Superoxide and Thymocyte for Liver Injury of Mice [Seite 367]
1.21.20 - 18.20 Gene Transfer of Kringle 1-5 and Related Assays for Mice with Hepatocellular Carcinoma [Seite 369]
1.21.21 - 18.21 Body Weight Assay for Mice with Liver Tumor Incidence [Seite 371]
1.21.22 - 18.22 P450 Activity and Inducibility in Rat Hepatocytes for Cytotoxicity Assay [Seite 372]
1.21.23 - 18.23 LDH Release in Rat Hepatocytes for Toxicity Assay [Seite 374]
1.21.24 - 18.24 Rainbow Trout Hepatocytes' EROD Activity Assay [Seite 375]
1.21.25 - 18.25 EROD Activity, ROS Production and Cytotoxic Concentration in Fish Hepatocytes for Drug Toxicity Assays [Seite 375]
1.21.26 - 18.26 Coho Salmon's IGF-I Gene Sequencing and TaqMan Assay [Seite 376]
1.21.27 - 18.27 DNA Strand Break in Rat Hepatocyte and Comet Assay [Seite 378]
1.21.28 - 18.28 DNA Laddering in Rat Hepatocyte and TUNEL Assay [Seite 379]
1.21.29 - 18.29 Counting Increases in Viable Cell Number for Hepatocyte Proliferation Assay [Seite 380]
1.21.30 - 18.30 Assay of HGF and TGF-? in CCL-64 Cells [Seite 382]
1.21.31 - 18.31 Assay for Serum IFN-? of Patients with Chronic Hepatitis C [Seite 382]
1.21.32 - 18.32 Rat Medium-Term Liver, DNA Microarray and Cu(+)-Reducing Antioxidation Assays for DEN-Induced Hepatocarcinogenesis [Seite 384]
1.21.33 - 18.33 Rat Medium-Term Liver Assay for DEN-Induced Hepatocarcinogenesis Assay [Seite 386]
1.21.34 - 18.34 Assay for Rat Carcinogenesis Initiated by Three Carcinogens [Seite 387]
1.21.35 - 18.35 Assay for Rat Carcinogenesis Initiated by Five Carcinogens [Seite 388]
1.21.36 - 18.36 Assay for DEN-Initiated Rat Carcinogenesis [Seite 389]
1.21.37 - 18.37 Assay for Normal Dose DEN-Initiated and Low Dose DEN-Maintained Rat Carcinogenesis [Seite 389]
1.21.38 - 18.38 TGF-?-Mediated Antiproliferation Assay [Seite 390]
1.21.39 - 18.39 Assay for DEN and HCB-Initiated Rat Carcinogenesis [Seite 391]
1.21.40 - References and Notes [Seite 391]
1.22 - 19 Methods and Applications of Estrogen Assays [Seite 399]
1.22.1 - 19.1 Yeast Estrogen Assay [Seite 400]
1.22.2 - 19.2 In Vivo, Ex Vivo, and In Vitro Assays for Estrogen-Like Effect [Seite 401]
1.22.3 - 19.3 Ameliorative Yeast Assay [Seite 402]
1.22.4 - 19.4 In Yeast Two-Hybrid Assay [Seite 403]
1.22.5 - 19.5 Estrogen-Sensitive Yeast Strain RMY/ER-ERE Assay [Seite 404]
1.22.6 - 19.6 Bioluminescent Yeast Assays [Seite 405]
1.22.7 - 19.7 LYES Assay [Seite 406]
1.22.8 - 19.8 ER? and ER? Stable Transactivation Assay [Seite 407]
1.22.9 - 19.9 HELN? and HELN? Transfected Cell Assay [Seite 408]
1.22.10 - 19.10 Luciferase Reporter Gene Assay [Seite 408]
1.22.11 - 19.11 Target AKT Pathway Assay [Seite 409]
1.22.12 - 19.12 Luciferase Assay [Seite 410]
1.22.13 - 19.13 Androgen Receptor Transactivation Assay [Seite 411]
1.22.14 - 19.14 Green Fluorescent Protein Expression Assay [Seite 413]
1.22.15 - 19.15 Luteinizing Hormone Releasing Hormone (LHRH) Assay [Seite 414]
1.22.16 - 19.16 Ishikawa Endometrial Cancer Cell Assay for Estrogen Receptor Expression [Seite 416]
1.22.17 - 19.17 Ishikawa Cell Assay for 11?-HSD2 Activity [Seite 416]
1.22.18 - 19.18 Ishikawa Cell Assay for Estrogen Activity [Seite 417]
1.22.19 - 19.19 Ishikawa Cell Assay for Plasminogen Activator Inhibitor-1 (PAI-1) [Seite 417]
1.22.20 - 19.20 Testosterone Induction Assay with Sertoli Cell [Seite 418]
1.22.21 - 19.21 Electrophoretic Mobility and Antibody Shift Assays [Seite 418]
1.22.22 - References and Notes [Seite 419]
1.23 - 20 Methods and Applications of Antimalarial Assays [Seite 423]
1.23.1 - 20.1 Plasmodium falciparum and Murine P388 Leukemia Cell Assay [Seite 424]
1.23.2 - 20.2 Antiplasmodial Activity Assay [Seite 424]
1.23.3 - 20.3 Plasmodium falciparum Growth In Vitro Assay [Seite 425]
1.23.4 - 20.4 Antibody Assay for Red Blood Cell Polymorphisms [Seite 426]
1.23.5 - 20.5 Leishmania Macrophage Assay [Seite 426]
1.23.6 - 20.6 Lactate Dehydrogenase-Based Antiplasmodial Assay [Seite 427]
1.23.7 - 20.7 Histidine-Rich Protein II Assay [Seite 427]
1.23.8 - 20.8 Histidine-Rich Protein II Assay [Seite 428]
1.23.9 - 20.9 Antimalarial Activity Assay [Seite 429]
1.23.10 - 20.10 Plasmodium yoelii Liver Stage Parasites Inhibition Assay [Seite 429]
1.23.11 - 20.11 In Vivo Antimalarial Assay [Seite 430]
1.23.12 - 20.12 ?-Hematin Inhibition Assay [Seite 431]
1.23.13 - 20.13 Non-radiolabeled Ferriprotoporphyrin IX Biomineralization Inhibition Assay [Seite 431]
1.23.14 - 20.14 Survival of Anopheles gambiae Assay [Seite 432]
1.23.15 - 20.15 Chloroquine Assay [Seite 433]
1.23.16 - 20.16 MS Assay for Quantification of Chloroquine in Dog Plasma [Seite 433]
1.23.17 - 20.17 Sensitive Fluorescence HPLC Assay for AQ-13 [Seite 434]
1.23.18 - 20.18 HPLC and HPTLC Assays for Chloroquine, Primaquine, and Bulaquine [Seite 435]
1.23.19 - 20.19 Real-Time PCR-Based Chloroquine Sensitivity Assay [Seite 436]
1.23.20 - 20.20 Rat Embryos In Vitro Assay [Seite 437]
1.23.21 - 20.21 HPLC-MS Assay for ?-DHA in Rat Plasma [Seite 439]
1.23.22 - 20.22 Plasmodium falciparum Clone and DHA Assay [Seite 440]
1.23.23 - References [Seite 441]
1.24 - 21 Methods and Applications of Cytogenetic Receptor and Enzyme Assays [Seite 445]
1.24.1 - 21.1 UT-7/EPO Cell Proliferation and Neutralizing Anti-EPO Antibody Assays [Seite 446]
1.24.2 - 21.2 Assay System for Biotin Protein Ligase (BPL) from Escherichia coli [Seite 448]
1.24.3 - 21.3 ?-Galactosidase and ?-Amylase Biosynthesis Assays [Seite 448]
1.24.4 - 21.4 Penicillin-Binding Protein (PBP 5) and Vancomycin Activity Assays [Seite 449]
1.24.5 - 21.5 Recombinant Bacteria Assay Evaluating Androgen Biosynthesis [Seite 450]
1.24.6 - 21.6 UDP-Glc 4-Epimerase Assay [Seite 452]
1.24.7 - 21.7 ATPs Exchange Assays [Seite 452]
1.24.8 - 21.8 Lux-Fluoro Assay for Combined Genotoxicity and Cytotoxicity [Seite 453]
1.24.9 - 21.9 Reporter Gene Assay for Aryl Hydrocarbon Receptor [Seite 453]
1.24.10 - 21.10 CYP1A Enzyme Assay [Seite 454]
1.24.11 - 21.11 CYP1A Activity (EROD) Assay [Seite 456]
1.24.12 - 21.12 Deubiquitinating Enzyme (DUB) Activity Assay [Seite 457]
1.24.13 - 21.13 Flow Cytometric Assay [Seite 458]
1.24.14 - 21.14 Serum Neutralization Assay Based on rHMPV-GFP [Seite 460]
1.24.15 - 21.15 Yellow Fluorescent Protein-Based Assay [Seite 461]
1.24.16 - 21.16 Red Fluorescent Cytotoxic T Lymphocyte Assay [Seite 463]
1.24.17 - 21.17 Green Fluorescent Protein-Based Assay [Seite 463]
1.24.18 - 21.18 DNA Break Assay in HepG2 Cells [Seite 465]
1.24.19 - References and Notes [Seite 465]
1.25 - Index [Seite 471]

Systemvoraussetzungen

Als PDF speichern Als Link merken